PUBLISHER: The Business Research Company | PRODUCT CODE: 1648619
PUBLISHER: The Business Research Company | PRODUCT CODE: 1648619
The companion animal arthritis refers to a condition involving inflammation of one or more joints in companion animals such as cats, dogs, and other exotic animals. Companion animal arthritis develops in the bones when the cartilage between joints becomes rougher and more worn, forcing the bone surfaces to rub against one another.
The main type of companion animal arthritis are dogs, cats, and others types. The dogs companion animal arthritis are used for controlling pain and inflammation in dogs. Dogs are domesticated canines (Canis familiaris) that are usually kept as pets or trained for hunting, guarding individuals or property. The companion animal arthritis indication are osteoarthritis and, other arthritis, that are treatment through medication, supplements and other treatment, which are sold and distributed through veterinary hospitals and clinics, retail pharmacies, online stores, and others.
The companion animal arthritis market research report is one of a series of new reports from The Business Research Company that provides companion animal arthritis market statistics, including companion animal arthritis industry global market size, regional shares, competitors with a companion animal arthritis market share, detailed companion animal arthritis market segments, market trends and opportunities, and any further data you may need to thrive in the companion animal arthritis industry. This companion animal arthritis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The companion animal arthritis market size has grown strongly in recent years. It will grow from $3.72 billion in 2024 to $4.08 billion in 2025 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to increasing pet ownership, advancements in veterinary medicine, awareness, and education.
The companion animal arthritis market size is expected to see rapid growth in the next few years. It will grow to $6.04 billion in 2029 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to aging pet population, innovations in therapeutics, customized nutrition, telemedicine in veterinary care, humanization of pets. Major trends in the forecast period include biologics in veterinary medicine, digital health solutions, nutraceuticals and functional foods, collaborations and partnerships, pet insurance impact, consumer demand for natural and holistic therapies, data-driven veterinary care.
Rising trend of pet adoption is expected to propel the growth of companion animal arthritis market. Pet adoption helps reduce stress, anxiety, depression, and so on. Pet adoption is a method of getting a dog, cat, and other exotic animals that their prior owners have given up to a shelter or rescue rather than getting one from a pet shop, breeder, or another individual. Pets face the risk of developing arthritis once they start getting into old age. For instance, according to a survey conducted by, The American Pet Products Association, a US-based not-for-profit industry association, approximately half of british homes with pets acquired at least one new animal while the country was in lockdown, while 11. 3 million Americans acquired new pets during the pandemic. Additionally, in the survey, 16% of Generation Z respondents and 13% of millennials stated they had adopted a new pet during the pandemic. Therefore, the rising trend of pet adoption contributes significantly to the growth of the companion animal arthritis market.
The increased spending on pet healthcare is anticipated to boost the demand for the companion animal arthritis market over the coming years. Spending on pet healthcare refers to the financial outlay for medical services and treatments aimed at maintaining or improving the well-being of domestic animals. Spending on companion animal arthritis care has risen steadily, reflecting a growing commitment to improving pets' well-being and quality of life. For instance, in 2022, according to the American Pet Products Association Inc., a US-based not-for-profit industry association, the expenditure on supplies, live animals, and OTC medicine is $31. 5 billion in 2022 compared to $32. 1 billion in 2023 and expenditure on veterinary care and products is $35. 9 billion in 2022 compared to 37 billion in 2023. Therefore, increased spending on pet healthcare is driving the growth of the companion animal arthritis market.
Leading companies in the companion animal arthritis market are increasingly concentrating on technological innovations, including advanced therapeutic products and supplements, to provide pets with effective pain relief and improved joint health, ultimately enhancing the quality of life for aging and arthritis-affected animals. One notable example is Bonqat, a new medication designed for cats that helps reduce anxiety during stressful situations, such as travel or veterinary visits, without causing sedation. This product aims to soothe cats, making it easier for both pets and their owners during trips or appointments. For instance, in April 2024, Zoetis Inc., a US-based company specializing in medicines and vaccinations for pets and livestock, launched Bonqat (pregabalin oral solution) to alleviate feline acute anxiety and fear associated with transportation and veterinary visits, which can hinder routine care. The oral solution can be mixed with food or administered directly to the cat, simplifying the process for pet owners. The dosing is minimal (0.1 mL/kg), and many cat owners have reported that administration is straightforward.
Major companies operating in the companion animal arthritis market are focused on developing stem cell treatments to gain a competitive edge in the market. Stem cell treatment is being explored as a promising therapy for animal arthritis, offering potential relief and regeneration of damaged joints. For instance, in January 2023, TVM, a UK-based animal health company, introduced DogStem, the first and only licensed stem cell therapy for canine osteoarthritis in Europe. This innovative treatment is designed for dogs with mild to severe hip and elbow osteoarthritis, and it has demonstrated effectiveness in reducing pain, alleviating lameness, and enhancing mobility and overall quality of life. DogStem boasts long-term efficacy, providing relief for dogs lasting anywhere from 3 to more than 12 months after a single injection. The key active ingredient in this product is mesenchymal stem cells derived from equine umbilical cords, known for their immunomodulatory and anti-inflammatory properties attributed to their paracrine activity.
In September 2022, Zoetis, a US-based animal health company, acquired NewMetrica for an undisclosed amount. This transaction would enhance Zoetis' capacities throughout the continuum of care, expand our grasp of quality-of-life evaluations, and result in a more profound comprehension of an animal's well-being. NewMetrica is a UK-based provider of scientifically-developed instruments to measure quality-of-life in animals such as canine arthritis.
Major companies operating in the companion animal arthritis market include Zoetis Inc., Merck Animal Health, Boehringer Ingelheim, Bayer Animal Health, Vetoquinol, Ceva Sante Animale, Dechra Pharmaceuticals, PetMed Express, Pet Health Solutions, VetriScience, Synlogic, Canine Arthritis Management, Integrative Pet Care, The Honest Kitchen, Vetri-Science Laboratories, Anivive Lifesciences, Pawsitively Posh Pets, Trifecta Natural, Nutramax Laboratories, Hill's Pet Nutrition, Royal Canin, Medivet, Virbac, Canna-Pet, Fetch for Pets, Lintbells, Allivet, Petlab Co.
North America was the largest region in the companion animal arthritis market in 2024. The regions covered in the companion animal arthritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the companion animal arthritis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.
The companion animal arthritis market includes revenues earned by entities by NSAIDs, monoclonal antibiotics. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Companion Animal Arthritis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on companion animal arthritis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for companion animal arthritis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The companion animal arthritis market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.